Ten63 Therapeutics is a venture-backed startup developing durable therapeutics against some of the most lethal diseases. It combines low-residual, ML-based computational chemistry and mathematically guaranteed, superlinear search algorithms to find optimized drug candidates. The company's platform, COPPER, leverages its proprietary AI and state-of-the-art physical models to explore an unprecedentedly large chemical space, allowing them to discover new therapeutics to targets previously believed undruggable.
Vitarka Therapeutics develops medical technology and solutions for various types of cancer. It is based in London, United Kingdom.
Beeflow applies scientific knowledge and technologies to bee pollination. Providing professional pollination services to farmers increases crop yields while reducing bee population decline. Since first started 4 years ago in Argentina, the company has increased between 20-90% crop yields in Blueberries, Almonds, Raspberries, and Kiwifruit.
Moirai Biodesign is a biotechnology company that develops RNA-based technologies for cancer-related diagnostics and therapeutics. The company develops non-invasive tests for the in-situ diagnosis of different types of cancer from a patient’s blood, in-vivo diagnosis systems for surgical assistance and patient monitoring, and therapeutical drugs for the treatment of cancer. Moirai Biodesign was founded in 2016 and is based in Barcelona, Spain.
Mirá is launching a biofuel breakthrough to subvert coal dependency in heavy industries.
BioLumen is a nutritional technology company that develops a patented dietary fiber technology platform that reduces the negative effect of a diet heavy in processed foods. BioLumen's technology is composed of insoluble dietary fiber matrix covered with a blend of food ingredients created from the latest drug delivery system research. The company's product, a nutraceutical, focuses on high risk individuals with prediabetes to help manage blood sugar levels, protect their liver from excess sugar and feed their gut microbiome, delivering health benefits. BioLumen was founded on 2018 and is headquartered in San Francisco, California.
QV Bioelectronics is striving to deliver longer, better quality lives to brain tumour patients through their first of its kind electric field therapy implant, GRACE. GRACE has been designed alongside some of the leading neurosurgeons in the UK, with the aim of extending patient life expectancy without impacting patient quality of life. For patients with the most common primary brain tumour, glioblastoma, there has been a severe lack of new, effective treatments for decades, with only a handful of approved options. Because of this, glioblastoma has some of the worst outcomes of any cancer, with a 5-year survival rate of <5. Co-founder and academic neurosurgeon Dr Richard Fu recognised this and was frustrated not only by the lack of treatments available for patients but also by major design flaws in newer electric field therapy approaches. Working together with Dr Chris Bullock, a biomedical engineer who had been carrying out research at Manchester's world-class materials research centres, they formed an elegant solution designed to optimise patient life-expectancy and quality of life. QV Bioelectronics was founded to their solution GRACE, to patients. Since then, their ground-breaking materials science research has received nearly $1M in financial awards from several UK institutions, including Innovate UK and the National Institute for Health Research in the UK, as well as over $1M in equity funding from international life science seed investors SOSV, and renowned life-science investors in Consilience & Catapult Ventures. QV now have an expert, multidisciplinary team with decades of experience working bringing GRACE to the clinic from their research hub in Alderley Park, Cheshire.
Unicorn Biotechnologies is developing a next-generation biomanufacturing platform to power the cell-based manufacturing revolution, starting with cultivated meat. By providing a clear path to affordably and rapidly scale cultivated meat, we will improve human and planetary health and drive the transition to animal-free agriculture.
Stämm Biotech specializes in life sciences. During the past two years, Stämm has designed a novel bioproduction system that leverages microfluidics, electroporation and robotics to solve the main constraint of the biotech industry: scaling up. Solving this problem could unlock a $700B market in the next 10 years. Today, after integrating these state-of-the-art technologies, the company is unveiling the future of biomanufacturing. Stämm downsized a whole biotech facility into an all-in-one, plug-n-play desktop unit: the Bioprocessor, which has proven to be at least 70x more productive than traditional bioreactors.
QuantumCyte is a technology platform company developing automated microdissection solutions for molecular pathology. Its automated tissue dissection system uses digital tissue maps to isolate ROIs that contain informative biomarkers for treatment decision support.
Inso Biosciences is an early-stage biotechnology company developing hardware platforms and tools for genomic sample handling. Our patented microfluidic technology, invented and developed at Cornell University, performs high-efficiency processing of cellular material, and we are exploring applications in long-read DNA extraction, multiomic sample processing, and pathogen surveillance. To find out more, please visit our website: www.inso.bio To get in touch with us, please email: contact@inso.bio
Circularis Biotechnologies develops a revolutionary technology to regulate gene expression and enable increased biotherapeutic production. It was founded in 2014 and is headquartered in Oakland, California.
At Unlocked, we develop probiotics that work - our strains are genetically optimized to digest compounds that can cause chronic health conditions. We accomplish this by activating dormant microbial abilities in a safe and well-established chassis. Our strains are rigorously tested and deliberately designed for the targeted elimination of specific compounds within the GI tract. Unlocked’s first product is designed to manage kidney stone risk by digesting a stone-forming compound that is absorbed from healthy foods such as leafy vegetables. We leverage alternative regulatory pathways to accelerate bringing safe and effective probiotics to patients that need them.
Gatehouse Bio is a biotech company developing effective therapeutics using AI that harnesses the power of small RNA. Their platform discovers disease-associated mutations and designs therapeutics to counteract their effect. We believe there is an RNA code that can treat every disease Our mission is to find that code and use it to develop effective therapeutics Our platform uses AI to discover mutations in small RNA genes and design oligonucleotides that crack a disease’s code Our pipeline and partnerships are focused on developing drugs for therapeutic areas with known heterogeneity (Fibrosis, Inflammation, Neurodegeneration) With every single code we break, we unlock the potential to improve the lives of many
CRIAM offers rapid and accurate blood typing and infectious diseases detection anywhere, enabling prompt and well-informed clinical decision-making. Our stand-alone platform is portable and does not require electricity nor additional equipment or laboratory infrastructure, ensuring accessibility and usability in diverse settings. In addition, our solution is highly scalable: one reader can perform several types of tests using specific cartridges and computer vision algorithms suitable for detecting a wide range of infectious diseases, thus consolidating market penetration.
Prolific Machines is a biotech company developing cell technologies to redefine how cells are produced for a sustainable and healthy future. It combines cutting-edge technologies to enable cell production at a new scale. The company was founded in 2020 and is based in San Francisco, California.
Synthace is a digital experiment platform built for life science R&D teams to help them run more powerful experiments. It digitizes experiments from end to end: with minimal training, scientists can design and plan reproducible experiments, simulate them ahead of time, run them on their automation equipment, and automatically structure all of their experimental data and metadata in a single place. Controlled from a browser window and needing no code to operate, it makes experiments easier to run in the lab, increases the scientific value of experiments, and also makes it possible to run experiments that were previously thought impossible.
Prothegen is a biotechnology company that develops cutting-edge medicines for precisely regulating cell death. The company is based in Palo Alto, California.
Prothegen is a biotechnology company that develops cutting-edge medicines for precisely regulating cell death. The company is based in Palo Alto, California.
Bisu is addressing the $47tn global longevity crisis by helping people live healthy, productive lives for longer. We provide affordable access to actionable health data at home, through easy, accurate urine and saliva tests. We enable personalized nutrition and lifestyle advice through proprietary microfluidic technology and scientific machine learning. Bisu is a graduate of the HAX accelerator and is backed by investors including SOSV, the world's leading health tech investor, and leading sports brand ASICS.
Indee Labs is developing hardware for gene delivery. Our hardware is uniquely positioned for the efficient development and scalable manufacture of gene-modified cell therapies such as chimeric antigen receptor T cells. The technology is being developed with the help of the Australian National Fabrication Facility. We are alumni of NSW Health, IndieBio, Y Combinator and MBC Biolabs (née QB3@953). We are opening up an office in Sydney and have lab space at Bonneville Labs in Berkeley.
Karma Biotechnologies is a Los Angeles startup dedicated to solving autoimmunity, allergies, and food sensitivities with our Xavine™ precision immunotherapy platform. General immune suppression is still the standard of care for most autoimmune disease patients; there is a critical unmet need to develop antigen-specific therapies that inhibit only the disease-causing rogue immune cells. To meet this need, Karma is leveraging expertise in immunology and lipid nanoparticle engineering to develop tolerogenic immunotherapies that elicit antigen-specific immune tolerance in vivo.
Helex uses its own genomics data, bioinformatics, and intelligent data-driven platform to create, verify, and distribute therapy-specific gRNAs. Founded in 2021 and is based in New York.
Helex uses its own genomics data, bioinformatics, and intelligent data-driven platform to create, verify, and distribute therapy-specific gRNAs. Founded in 2021 and is based in New York.
Rizlab Health enables practitioners and patients to acquire full blood count readings in minutes. Founded in 2018 and is based in East Princeton.
Rizlab Health enables practitioners and patients to acquire full blood count readings in minutes. Founded in 2018 and is based in East Princeton.
Microgenesis offers a new fertility test and personalized nutritional supplementation that restores the fertility potential of women everywhere. Microgenesis has proven their validity in tough cases – women who have already failed multiple IVF implantations. Now, they are bringing their solution downmarket to OB-GYNs and D2C, operating out of a CLIA lab in Oakland. Microgenesis’ diagnostic detects subclinical inflammation that harms ovarian function and implantation. Their three-month treatment is drug-free and all-natural.
Getting drugs through the tumor barrier and across the blood brain barrier is a well-known, major challenge for medicine. Advanced Microbubbles uses tiny uniform bubbles, which are agitated with ultrasound at the site of a tumor, to open up the barriers so drugs can enter locally. Their bubbles can be delivered alongside the desired drug, or conjugated to many drugs.
Protera builds functional ingredients for the food industry using protein engineering and artificial intelligence. Their agency streamlines protein design and development with a proprietary deep-learning algorithm, to predict high-value protein products and enzymes with unprecedented speed, enabling customers to get healthy, safe foods made from ingredients that are produced responsibly and sustainably.
Filtricine, Inc. is a venture-backed, clinical stage biotech company based in Santa Clara, CA. We are developing a nutrient modulation platform which can identify metabolic vulnerabilities in cancers and exploit those vulnerabilities without the use of drugs.
RxAll is a Deep Learning-Hyperspectral IoT Platform for instant authentication and real-time global tracking of quality of drugs- prescription & OTC meds., opioids, recreational drugs and cannabis- through mobile phones and a cloud based platform. We deliver authenticated medicines to hospitals, pharmacies and patients.
QV Bioelectronics is striving to deliver longer, better quality lives to brain tumour patients through their first of its kind electric field therapy implant, GRACE. GRACE has been designed alongside some of the leading neurosurgeons in the UK, with the aim of extending patient life expectancy without impacting patient quality of life. For patients with the most common primary brain tumour, glioblastoma, there has been a severe lack of new, effective treatments for decades, with only a handful of approved options. Because of this, glioblastoma has some of the worst outcomes of any cancer, with a 5-year survival rate of <5. Co-founder and academic neurosurgeon Dr Richard Fu recognised this and was frustrated not only by the lack of treatments available for patients but also by major design flaws in newer electric field therapy approaches. Working together with Dr Chris Bullock, a biomedical engineer who had been carrying out research at Manchester's world-class materials research centres, they formed an elegant solution designed to optimise patient life-expectancy and quality of life. QV Bioelectronics was founded to their solution GRACE, to patients. Since then, their ground-breaking materials science research has received nearly $1M in financial awards from several UK institutions, including Innovate UK and the National Institute for Health Research in the UK, as well as over $1M in equity funding from international life science seed investors SOSV, and renowned life-science investors in Consilience & Catapult Ventures. QV now have an expert, multidisciplinary team with decades of experience working bringing GRACE to the clinic from their research hub in Alderley Park, Cheshire.
BioROSA Technologies creates a biologically-based diagnostic standard of care for Autism Spectrum Disorders. The company was founded in 2018 and is based in Belmont, Massachusetts.
Beeflow applies scientific knowledge and technologies to bee pollination. Providing professional pollination services to farmers increases crop yields while reducing bee population decline. Since first started 4 years ago in Argentina, the company has increased between 20-90% crop yields in Blueberries, Almonds, Raspberries, and Kiwifruit.
QuantumCyte is a technology platform company developing automated microdissection solutions for molecular pathology. Its automated tissue dissection system uses digital tissue maps to isolate ROIs that contain informative biomarkers for treatment decision support.
Diadem Biotherapeutics is a biotechnology company that focuses on creating bio-therapeutical materials produced using organic means. Diadem develops exosomes to treat chronic inflammatory and auto-immune conditions.
Jointechlabs is an emerging world leader in point-of-care regenerative medicine therapies with its headquarters in Brandon, FL (outside Tampa). Current products include MiniTC® (for USA) and Mini-Stem System® (for Ex-USA) - medical devices that allow processing of autologous (your own) body fat for use in non-surgical orthopedic and aesthetic procedures in your doctor’s office, providing safe, time efficient, and superior results. Pipeline products include biologic drugs and 3D Bioprinted products to further expand use in orthopedic, wound healing and plastic and reconstructive surgery . For more information, please visit: https://jointechlabs.com/.
CyGenica uses a non-viral, non-toxic platform to develop in vitro and in vivo delivery solutions for drugs, gene editing components, and antibiotics.
BiomeSense is developing the first technology platform for continuous, at-home monitoring of the human gut microbiome, transforming the ability to understand & utilize the microbiome for precision medicine. The enabling technology is the GutLab, the first “smart bathroom” system for at-home microbiome monitoring, which is combined with the MetaBiome time-series analytics platform into a single end-to-end solution. The platform allows scientists, patients, and consumers the unprecedented ability to tie microbiome changes directly to clinical outcomes in real time, revolutionizing the ability to leverage the microbiome for better health.
Stämm Biotech specializes in life sciences. During the past two years, Stämm has designed a novel bioproduction system that leverages microfluidics, electroporation and robotics to solve the main constraint of the biotech industry: scaling up. Solving this problem could unlock a $700B market in the next 10 years. Today, after integrating these state-of-the-art technologies, the company is unveiling the future of biomanufacturing. Stämm downsized a whole biotech facility into an all-in-one, plug-n-play desktop unit: the Bioprocessor, which has proven to be at least 70x more productive than traditional bioreactors.
Protera builds functional ingredients for the food industry using protein engineering and artificial intelligence. Their agency streamlines protein design and development with a proprietary deep-learning algorithm, to predict high-value protein products and enzymes with unprecedented speed, enabling customers to get healthy, safe foods made from ingredients that are produced responsibly and sustainably.
Impact Biosystems develops hardware and software solutions for people in the health and fitness space. They provide hardware-connected recovery platforms that provide users with custom measurements of their bodies and enhance the gamifying and socializing experience.
FluidAI Medical is a medical platform company at the forefront of revolutionizing global patient care, leveraging the transformative power of artificial intelligence in post-operative recovery.
Harae Dx Corp. is a medical diagnostics company which has developed the worlds smallest, portable, automated multi early cancer detection system
In the biotech space, cell and gene therapy and clean meat are two of the most promising industries. Yet both are facing the same issue: large-scale cell culture remains the blocking point to scale up and make both cell and gene therapies and clean meat accessible and affordable. To that end, Kolibri is building a proprietary cell-engineering platform, combining cutting edge techniques in acoustics and biology, allowing for a 90x higher yield while decreasing production costs up to 50x.
Synthace is a digital experiment platform built for life science R&D teams to help them run more powerful experiments. It digitizes experiments from end to end: with minimal training, scientists can design and plan reproducible experiments, simulate them ahead of time, run them on their automation equipment, and automatically structure all of their experimental data and metadata in a single place. Controlled from a browser window and needing no code to operate, it makes experiments easier to run in the lab, increases the scientific value of experiments, and also makes it possible to run experiments that were previously thought impossible.
Unicorn Biotechnologies is developing a next-generation biomanufacturing platform to power the cell-based manufacturing revolution, starting with cultivated meat. By providing a clear path to affordably and rapidly scale cultivated meat, we will improve human and planetary health and drive the transition to animal-free agriculture.
Medical Devices Corner specializes in providing commercial medical products.
Prolific Machines is a biotech company developing cell technologies to redefine how cells are produced for a sustainable and healthy future. It combines cutting-edge technologies to enable cell production at a new scale. The company was founded in 2020 and is based in San Francisco, California.
Wayfinder Biosciences is a biotechnology company developing orally available small molecule drugs that modulate the function of the RNAs encoding key disease targets. The company's proprietary platform combines unique screening and computational technologies to rapidly discover potent, selective and biologically active RNA-targeting small molecules. Wayfinder's programs are focused on traditionally inaccessible targets in oncology and neurodegenerative disease. Wayfinder Biosciences was established in 2021 and is headquartered in Seattle, WA.
Feel Therapeutics is a digital precision medicine company delivering objective data and passive measurement for mental health. The company develops physiological and digital biomarkers and therapeutics for mental health. Its Feel data monitoring device leverages five embedded sensors via the wristband. Feel collects biometric data and analyzes them using the latest cutting-edge methods of computer science to develop digital biomarkers.
Basin Genomics is combining scientific backgrounds in genomics and oncology with startup expertise to translate genetic discoveries into advances in personalized clinical care as it strives to develop technology that will decrease the rates of cervical cancer globally.
Basin Genomics is combining scientific backgrounds in genomics and oncology with startup expertise to translate genetic discoveries into advances in personalized clinical care as it strives to develop technology that will decrease the rates of cervical cancer globally.
Dalton Bioanalytics is a developer of analytical technology that unlocks access to the wealth of information available in the blood. It resolves the inefficiency and expense that plagues traditional laboratory testing by digitizing the biochemical composition of blood and translating that digital signature into a comprehensive array of actionable health insights. The analytical technology deciphers the biochemical signature of blood to build narratives about internal biology. Dalton was headquartered in Los Angeles, California in 2019.
Mimio Health is a nutraceutical company focusing on the research and production of mimetic supplements. Its patent-pending fasting mimetic formulation uses a rigorously selected combination of the same bioactive human metabolites that induce this regenerative "bio-program" to replicate the body’s natural response to fasting without having to fast.
Mimio Health is a nutraceutical company focusing on the research and production of mimetic supplements. Its patent-pending fasting mimetic formulation uses a rigorously selected combination of the same bioactive human metabolites that induce this regenerative "bio-program" to replicate the body’s natural response to fasting without having to fast.
Microgenesis offers a new fertility test and personalized nutritional supplementation that restores the fertility potential of women everywhere. Microgenesis has proven their validity in tough cases – women who have already failed multiple IVF implantations. Now, they are bringing their solution downmarket to OB-GYNs and D2C, operating out of a CLIA lab in Oakland. Microgenesis’ diagnostic detects subclinical inflammation that harms ovarian function and implantation. Their three-month treatment is drug-free and all-natural.
Gatehouse Bio is a biotech company developing effective therapeutics using AI that harnesses the power of small RNA. Their platform discovers disease-associated mutations and designs therapeutics to counteract their effect. We believe there is an RNA code that can treat every disease Our mission is to find that code and use it to develop effective therapeutics Our platform uses AI to discover mutations in small RNA genes and design oligonucleotides that crack a disease’s code Our pipeline and partnerships are focused on developing drugs for therapeutic areas with known heterogeneity (Fibrosis, Inflammation, Neurodegeneration) With every single code we break, we unlock the potential to improve the lives of many
Powered by AI, EMBER is the mobile telehealth platform patients use to get better faster. EMBER connects you with a medical professional within minutes via private message or video call. Get the care that’s right for you—all in a simple, easy-to-use mobile app. Because affordable, personalized care starts before you get to the waiting room. Learn more at embermed.com.
Ten63 Therapeutics is a venture-backed startup developing durable therapeutics against some of the most lethal diseases. It combines low-residual, ML-based computational chemistry and mathematically guaranteed, superlinear search algorithms to find optimized drug candidates. The company's platform, COPPER, leverages its proprietary AI and state-of-the-art physical models to explore an unprecedentedly large chemical space, allowing them to discover new therapeutics to targets previously believed undruggable.
Gatehouse Bio is a biotech company developing effective therapeutics using AI that harnesses the power of small RNA. Their platform discovers disease-associated mutations and designs therapeutics to counteract their effect. We believe there is an RNA code that can treat every disease Our mission is to find that code and use it to develop effective therapeutics Our platform uses AI to discover mutations in small RNA genes and design oligonucleotides that crack a disease’s code Our pipeline and partnerships are focused on developing drugs for therapeutic areas with known heterogeneity (Fibrosis, Inflammation, Neurodegeneration) With every single code we break, we unlock the potential to improve the lives of many
Transforming the performance of protein powders through our patent-pending Ingredient Optimization process to increase sustainability and improve health outcomes.
BiomeSense is developing the first technology platform for continuous, at-home monitoring of the human gut microbiome, transforming the ability to understand & utilize the microbiome for precision medicine. The enabling technology is the GutLab, the first “smart bathroom” system for at-home microbiome monitoring, which is combined with the MetaBiome time-series analytics platform into a single end-to-end solution. The platform allows scientists, patients, and consumers the unprecedented ability to tie microbiome changes directly to clinical outcomes in real time, revolutionizing the ability to leverage the microbiome for better health.
RxAll is a Deep Learning-Hyperspectral IoT Platform for instant authentication and real-time global tracking of quality of drugs- prescription & OTC meds., opioids, recreational drugs and cannabis- through mobile phones and a cloud based platform. We deliver authenticated medicines to hospitals, pharmacies and patients.
Leveraging single cell high-throughput biology and AI/ML to dramatically increase the success of cancer therapy.
BioFeyn is improving what farmed fish eat. By optimizing marine ingredients so fish can get more of what they naturally get in the ocean, gains in efficiency and sustainability are improved across the industry. Through a specialized method of biodegradable nanoencapsulations, trace amounts of marine ingredients are surrounded by a shell of other naturally-derived compounds. This ensures better digestion, absorption, bioavailability, and delivery to target tissues in the animals to help them grow and remain healthy.
AsimicA focuses on developing novel technologies for improved production in Microbial Biosynthetic Factories. Their technologies have the potential for a multi-fold increase in yields of biosynthetic processes. Since relatively low yields of target products, made through the biosynthesis is the major limitation of biotechnology, our innovative approaches for production may revolutionize the industry. AsimicA was launched in November 2018, by Nikolai Mushnikov and Grant Bowman.
Impact Biosystems develops hardware and software solutions for people in the health and fitness space. They provide hardware-connected recovery platforms that provide users with custom measurements of their bodies and enhance the gamifying and socializing experience.
Moirai Biodesign is a biotechnology company that develops RNA-based technologies for cancer-related diagnostics and therapeutics. The company develops non-invasive tests for the in-situ diagnosis of different types of cancer from a patient’s blood, in-vivo diagnosis systems for surgical assistance and patient monitoring, and therapeutical drugs for the treatment of cancer. Moirai Biodesign was founded in 2016 and is based in Barcelona, Spain.
BioAesthetics was founded in 2015 as a Tulane University spin-out with the mission to improve reconstruction options for breast cancer patients after they undergo mastectomies. The BioAesthetics’ initial product is a tissue-engineered nipple-areolar complex (NAC). This product will be provided to plastic and reconstructive surgeons as an off-the-shelf ready, acellular, NAC graft. During the breast reconstruction phase, after a mastectomy, the surgeon would engraft the NAC graft in position onto the patient’s reconstructed breast. The patient’s body would then use this NAC graft as a building frame to regenerate their own NAC. This patent-pending product is currently in the pre-clinical phase.
BioFeyn is improving what farmed fish eat. By optimizing marine ingredients so fish can get more of what they naturally get in the ocean, gains in efficiency and sustainability are improved across the industry. Through a specialized method of biodegradable nanoencapsulations, trace amounts of marine ingredients are surrounded by a shell of other naturally-derived compounds. This ensures better digestion, absorption, bioavailability, and delivery to target tissues in the animals to help them grow and remain healthy.
Optimize Health is a provider of a digital healthcare platform that enables the deployment of Remote Patient Monitoring (RPM) programs. It uses easy-to-use equipment and software. The software is designed to facilitate provider compliance when billing to new Medicare CPT codes for RPM while providing a great user experience for both patients and providers. Its system is designed to be profitable for physicians starting in the first month.
Renegade.bio is a biotechnology startup dedicated to developing and deploying high throughput diagnostics for the detection of novel infectious diseases.
Synthetix is a new financial primitive enabling the creation of synthetic assets, offering unique derivatives and exposure to real-world assets on the blockchain. Synthetix powers decentralized perpetual futures, options markets, deal coordination markets, and more. Synthetix was established in 2017 by Kain Warwick in Sydney, New South Wales.
To address the exploding demand for efficacious mental healthcare globally, Mobio Interactive has developed and commercialised an AI-powered digital theragnostic platform that delivers clinically validated psychotherapy programmes personalised to every patient using digital biomarkers that quantify human brain states without relying on a wearable.
rocketship.vc is an early-stage venture capital fund investing in companies using models built through data science. Their proprietary Escape Velocity algorithm identifies companies with a Sustainable Growth Engine at their core. It was founded in 2014 and is headquartered in Los Altos, California, United States.
Microgenesis offers a new fertility test and personalized nutritional supplementation that restores the fertility potential of women everywhere. Microgenesis has proven their validity in tough cases – women who have already failed multiple IVF implantations. Now, they are bringing their solution downmarket to OB-GYNs and D2C, operating out of a CLIA lab in Oakland. Microgenesis’ diagnostic detects subclinical inflammation that harms ovarian function and implantation. Their three-month treatment is drug-free and all-natural.
QV Bioelectronics is striving to deliver longer, better quality lives to brain tumour patients through their first of its kind electric field therapy implant, GRACE. GRACE has been designed alongside some of the leading neurosurgeons in the UK, with the aim of extending patient life expectancy without impacting patient quality of life. For patients with the most common primary brain tumour, glioblastoma, there has been a severe lack of new, effective treatments for decades, with only a handful of approved options. Because of this, glioblastoma has some of the worst outcomes of any cancer, with a 5-year survival rate of <5. Co-founder and academic neurosurgeon Dr Richard Fu recognised this and was frustrated not only by the lack of treatments available for patients but also by major design flaws in newer electric field therapy approaches. Working together with Dr Chris Bullock, a biomedical engineer who had been carrying out research at Manchester's world-class materials research centres, they formed an elegant solution designed to optimise patient life-expectancy and quality of life. QV Bioelectronics was founded to their solution GRACE, to patients. Since then, their ground-breaking materials science research has received nearly $1M in financial awards from several UK institutions, including Innovate UK and the National Institute for Health Research in the UK, as well as over $1M in equity funding from international life science seed investors SOSV, and renowned life-science investors in Consilience & Catapult Ventures. QV now have an expert, multidisciplinary team with decades of experience working bringing GRACE to the clinic from their research hub in Alderley Park, Cheshire.
Prolific Machines is a biotech company developing cell technologies to redefine how cells are produced for a sustainable and healthy future. It combines cutting-edge technologies to enable cell production at a new scale. The company was founded in 2020 and is based in San Francisco, California.
Bisu is addressing the $47tn global longevity crisis by helping people live healthy, productive lives for longer. We provide affordable access to actionable health data at home, through easy, accurate urine and saliva tests. We enable personalized nutrition and lifestyle advice through proprietary microfluidic technology and scientific machine learning. Bisu is a graduate of the HAX accelerator and is backed by investors including SOSV, the world's leading health tech investor, and leading sports brand ASICS.